FDA’s “Regulator/Advocate” Makes Headlines
This article was originally published in RPM Report
The New York Times profiles Richard Pazdur on the front page, reflecting his new role as “regulator/advocate” following his wife’s cancer diagnosis.
You may also be interested in...
Before taking over the US health department, Alex Azar helped bring landmark litigation challenging the scope of FDA’s regulatory authority under the First Amendment. Now his tenure is ending with a First Amendment defense of the agency.
In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.
Meeting to address opioid abuse crisis was also a trial of whether FDA could conduct important public business using online-only technology.